Clinical Research

TAVR linked to better long-term health status than SAVR

Patients with severe aortic stenosis who undergo TAVR enjoy a minor but significant sustained health benefit that isn’t mirrored in patients who opt for surgical AVR, according to research reported at TCT 2019 in San Francisco.

October 3, 2019

3-year COAPT results bolster MitraClip’s success

Results from the COAPT study continue to roll in, and it was all positive news for the MitraClip team at the TCT conference in San Francisco this month.

September 30, 2019

ABSORB III: 5-year results offer renewed hope for bioresorbable stents

Five-year results of the ABSORB III trial suggest that, while target lesion failure and scaffold thrombosis have remained apparent in patients implanted with bioresorbable vascular scaffolds, the poor outcomes associated with BVS seemed to subside after three years, when the stents had completely dissolved.

September 26, 2019
NASA astronaut Kate Rubins culturing heart cells in space in 2019. Image courtesy of NASA

What CV research looks like in space

Researchers on the International Space Station are leveraging the microgravity conditions within the ISS U.S. National Laboratory to study heart cells in ways we can’t on the ground.

August 13, 2019

ADHD medication can negatively impact child brain development

A commonly prescribed drug used to treat attention-deficit/hyperactivity disorder (ADHD) disproportionately affects the development of children’s brains compared to adults with ADHD, according to a new study published in Radiology.

August 13, 2019

Ambra Health and Google Cloud Collaborate to Advance Healthcare Research with Anonymized Medical Imaging Data

Ambra Health, makers of the leading cloud-based, medical image management suite, today announced a new collaboration with Google Cloud to advance healthcare research with anonymized medical imaging data.

November 26, 2018
The Abbott MitraClip is the primary structural heart device used in transcatheter edge-to-edge repairs (TEER) of the mitral valve leaflets. The results of the COAPT trial dropped like a thunderclap Sunday at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, with several cardiologists predicting the MitraClip device will have a swift and lasting impact on the treatment of heart failure patients.

TCT.18: COAPT draws superlatives, raises questions about replicating MitraClip’s benefits

Compared to heart failure patients with severe secondary mitral regurgitation who were treated with guideline-directed medical therapy alone, those randomized to a MitraClip procedure plus optimal medical therapy demonstrated relative reductions of 47 percent for heart failure hospitalizations and 38 percent for mortality at two years of follow-up.

September 23, 2018
heart

Tafamidis shows promise for treating cardiac amyloidosis

Research presented this week at the European Society of Cardiology Congress in Munich suggests a new treatment may be emerging for transthyretin amyloid cardiomyopathy—a condition previously thought to be rare and untreatable.

August 28, 2018